Myocardial substrate metabolism in obesity
1Department of Cardiovascular Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, John Radcliffe Hospital, Oxford, UK.
International Journal of Obesity (2005)
|October 17, 2012
Summary
Obesity causes inefficient cardiac metabolism, increasing heart failure risk. Targeting these mitochondrial changes may prevent and treat obesity-related heart problems.
Area of Science:
- Cardiology
- Metabolic Research
- Biochemistry
Background:
- Obesity is associated with diverse cardiac alterations, ranging from diastolic dysfunction to systolic heart failure.
- Cardiac metabolism is significantly altered in obesity, impacting adenosine triphosphate (ATP) production and utilization efficiency.
Purpose of the Study:
- To investigate the metabolic changes in the heart associated with obesity.
- To identify potential therapeutic targets for obesity-related heart failure.
Main Methods:
- Analysis of gene and protein expression related to fatty acid and glucose metabolism in cardiac tissue.
- Assessment of mitochondrial function and efficiency in the context of obesity-induced metabolic shifts.
Main Results:
- Obesity leads to upregulation of fatty acid metabolism proteins and inhibition of glucose utilization pathways.
- Altered mitochondrial electron transport chain proteins decrease the efficiency of ATP production, increasing oxygen consumption.
- These metabolic dysfunctions contribute to the increased incidence of heart failure in obese individuals.
Conclusions:
- Obesity-induced changes in cardiac mitochondrial metabolism impair cardiac efficiency and contribute to heart failure.
- Targeting these specific mitochondrial metabolic pathways presents a promising therapeutic strategy for preventing and treating obesity-related heart conditions.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:19Regulation of Metabolism
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...